<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21976132</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0142</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>71</EndPage><MedlinePgn>63-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.26204</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC inhibitor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In phase 1, 16 men received dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m(2) every 21 days. In phase 2, 30 additional men received dasatinib 100 mg once daily/docetaxel 75 mg/m(2) every 21 days. Efficacy endpoints included changes in prostate-specific antigen (PSA), measurable disease, bone scans, and markers of bone metabolism. Safety and pharmacokinetics were also studied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Combination dasatinib and docetaxel therapy was generally well tolerated. Thirteen of 46 patients (28%) had a grade 3-4 toxicity. Drug-drug interactions and a maximum tolerated dose were not identified. Durable 50% PSA declines occurred in 26 of 46 patients (57%). Of 30 patients with measurable disease, 18 (60%) had a partial response. Fourteen patients (30%) had disappearance of a lesion on bone scan. In bone marker assessments, 33 of 38 (87%) and 26 of 34 (76%) had decreases in urinary N-telopeptide or bone-specific alkaline phosphatase levels, respectively. Twenty-eight patients (61%) received single-agent dasatinib after docetaxel discontinuation and had stabilization of disease for an additional 1 to 12 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The high objective response rate and favorable toxicity profile are promising and justify randomized studies of docetaxel and dasatinib in castration-resistant PC. Parallel declines in levels of PSA and bone markers are consistent with cotargeting of epithelial and bone compartments of the cancer. Treatment with single-agent dasatinib following docetaxel cessation warrants further study. Cancer 2012;. &#xa9; 2011 American Cancer Society.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. johna@mdanderson.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Braud</LastName><ForeName>Edward L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Posadas</LastName><ForeName>Edwin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lonberg</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gallick</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Trudel</LastName><ForeName>G&#xe9;ralyn C</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Paliwal</LastName><ForeName>Prashni</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Shruti</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Logothetis</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00439270</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>L30 AR053003</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 CA140388</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA180-086</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>RBZ1571X5H</RegistryNumber><NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002369" MajorTopicYN="N">Castration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of Interest:</b> GCT is an employee of and owns stocks in Bristol-Myers Squibb. PP and SA are employees of Bristol-Myers Squibb. AJA has received research funding from and acted in a consultant/advisory role for Bristol-Myers Squibb, has received research funding and honoraria from sanofi-aventis, and received research funding from ImClone and Medivation. CJL has acted in a consultant/advisory role for and received research funding and honoraria from Bristol-Myers Squibb. JCA, PM, ELB, EP, ML, and GEG have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21976132</ArticleId><ArticleId IdType="mid">NIHMS494060</ArticleId><ArticleId IdType="pmc">PMC3898168</ArticleId><ArticleId IdType="doi">10.1002/cncr.26204</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soloway MS, Ishikawa S, van der Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology. 1989;33:53&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">2775378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst DS, Hanson J, Venner PM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol. 1991;146:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1856934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071289</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88:195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377050</ArticleId><ArticleId IdType="pubmed">12610502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">11210994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Ye XC, Chu K, et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007;67:6544&#x2013;6548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000837</ArticleId><ArticleId IdType="pubmed">17638862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res. 2010;16:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802676</ArticleId><ArticleId IdType="pubmed">20028742</ArticleId></ArticleIdList></Reference><Reference><Citation>Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer. 2003;39:1927&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185&#x2013;9189.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230377</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323&#x2013;3333.</Citation><ArticleIdList><ArticleId IdType="pubmed">18451159</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720213</ArticleId><ArticleId IdType="pubmed">19603032</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg-Furmanov M, Stein I, Pikarsky E, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 2004;64:1058&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">14871838</ArticleId></ArticleIdList></Reference><Reference><Citation>Posadas EM, Al-Ahmadie H, Robinson VL, et al. FYN is overexpressed in human prostate cancer. BJU Int. 2009;103:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741693</ArticleId><ArticleId IdType="pubmed">18990162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:3540&#x2013;3549.</Citation><ArticleIdList><ArticleId IdType="pubmed">19447874</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem. 2004;279:17660&#x2013;17666.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739300</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992;90:1622&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC443211</ArticleId><ArticleId IdType="pubmed">1383278</ArticleId></ArticleIdList></Reference><Reference><Citation>Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003;63:5028&#x2013;5033.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941830</ArticleId></ArticleIdList></Reference><Reference><Citation>Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318:161&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">16627750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749247</ArticleId><ArticleId IdType="pubmed">19573813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658&#x2013;6661.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615512</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67:2226&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">17721511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461&#x2013;3467.</Citation><ArticleIdList><ArticleId IdType="pubmed">10550143</ArticleId></ArticleIdList></Reference><Reference><Citation>Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010133</ArticleId><ArticleId IdType="pubmed">18309951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541900</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421&#x2013;7428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394097</ArticleId><ArticleId IdType="pubmed">19920114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu EY, Massard C, Gross M, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085) J Clin Oncol. 2009;27(suppl 15):270s. Abstract 5147.</Citation></Reference><Reference><Citation>Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112:326&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">17960793</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14:6270&#x2013;6276.</Citation><ArticleIdList><ArticleId IdType="pubmed">18829508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007;13:5816&#x2013;5824.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908974</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>